32 results about "Betaine-aldehyde dehydrogenase" patented technology

The present invention provides compositions comprising therapeutic nucleic acids such as interfering RNA (e.g., dsRNA such as siRNA) that target aldehyde dehydrogenase (ALDH) gene expression, lipid particles comprising one or more (e.g., a cocktail) of the therapeutic nucleic acids, methods of making the lipid particles, and methods of delivering and / or administering the lipid particles (e.g., for treating alcoholism in humans).

The present invention provides compositions comprising therapeutic nucleic acids such as interfering RNA (e.g., dsRNA such as siRNA) that target aldehyde dehydrogenase (ALDH) gene expression, lipid particles comprising one or more (e.g., a cocktail) of the therapeutic nucleic acids, methods of making the lipid particles, and methods of delivering and / or administering the lipid particles (e.g., for treating alcoholism in humans).

The invention discloses ALDH1A (aldehyde dehydrogenase 1A), an agonist and a catalysate of the ALDH1A, and an application of an inhibitor. Particularly, the invention discloses the application of theALDH1A or the agonist or the catalysate, the ALDH1A is used to prepare a pharmaceutical composition or preparation, and the pharmaceutical composition or preparation is used to treat and / or prevent infantile autism.

The invention discloses a primer and a detection method which can detect a screened molecular marker aiming at aromatic rice with multiple types of aroma genes and amplify a molecular marker of multiple types of betaine aldehyde dehydrogenase genes 2 (Badh2 / badh2) which are directly related to rice aroma formation. The detection method comprises the following steps: (1) extracting total DNAs of the rice as a template, and adding the primer for performing polymerase chain reaction (PCR) amplification; (2) performing restriction endonuclease Alu I digestion on a PCR product; (3) performing gel electrophoresis detection on an enzyme-digested product. The situation that only a mutation type of the aroma allele can be identified in the process of detecting a molecular marker of aroma genes in the past is broken, plants containing different types of the aroma genes can be selected in an assisted mode, a mutation type of the aroma allele of a parent aromatic rice variety is not required to determined before the operation of performing novel aromatic rice variety breeding on the molecular marker in an assisted mode, and pre-operation steps of molecular marker-assisted breeding are simplified, so that a breeding objective for breeding a novel aromatic rice variety is rapidly and effectively realized.

The invention relates to a method for designing gene sequences, in particular to a human aldehyde dehydrogenase 2 sequence designed according to a preferred codon of pichia pastoris. The sequence is characterized in that a DNA molecule is designed according to the preference of the pichia pastoris, and a code of the molecule has the same nucleotide sequence as a protein coded by a human aldehyde dehydrogenase 2 gene ID 217 on an amino acid level. The human aldehyde dehydrogenase 2 gene sequence designed according to the preferred codon of pichia pastoris is realized by the following steps: on the basis of a human ALDH2 gene (gene ID 217), UTR and signal peptide are deleted; enzyme cutting sites of an incision enzyme EcoR I and an incision enzyme Not I are added; a codon GCG for coding Ala is replaced by GCU according to the use method of the pichia pastoris codon, and codons CGC and CGG for coding Arg are replaced by AGA, AGG, CGU and CGA; and altogether 28 bases are modified to obtain a target sequence ALDH2. The gene sequence can express with high efficiency in the pichia pastoris, can be applied to preventing alcoholism and protecting livers and has the effects of preventing alcoholism and protecting livers.

The invention relates to thermophilic long-chain alkyl aldehyde dehydrogenase in an n-alkane end degradation process of thermophilic denitrified bacillus and a crystal structure thereof. A molecular clone method is utilized, so that a target gene is cloned into escherichia coli (E. coli) so as to be heterologously expressed. A purified product of aldehyde dehydrogenase is obtained through a protein purification method. A crystal of the aldehyde dehydrogenase, which is suitable for diffraction, is obtained through a hanging droplet crystallization method. The crystal structure of the aldehyde dehydrogenase is analyzed by utilizing an X-ray diffraction method. The results show that the aldehyde dehydrogenase contains a characteristic ALDH fold which is formed by three structural domains. Site-specific mutagenesis is carried out on conserved residues on an enzyme activity part, and the influence of the conserved residues on enzyme activity is proved through wild type of the enzyme and enzyme activity experiment of the mutant thereof. The results can comprehensively reflect space conformation of the enzyme, and provide theoretical guidance for further researching relation between structures and functions of the aldehyde dehydrogenase, and improving the degradation activity of the enzyme.

The invention discloses new genes for encoding clonorchis sinensis type I aldehyde dehydrogenase, polypeptides encoded by the genes, and antibody of the polypeptides. The invention also discloses the depressor of the polypeptides for screening clonorchis sinensis type I aldehyde dehydrogenase, the use of polynucleotides as primer or as probe, in particular the use of the polypeptide and polynucleotide as diagnosis reagent kit, and vaccine.

The invention discloses an application of acetaldehyde dehydrogenase 2 as a drug target for treating tumor cells with anthracycline type chemotherapy drugs. Drug screening shows that the anthracycline type chemotherapy drugs can specifically kill renal clear cell cancer cells with VHL deletion or mutation and has small toxicity to normal cells, thus providing an effective choice for chemotherapy of renal cancer and overcoming the disadvantage that the renal cancer is only treated through operations in clinical at present. Further study shows the sensitivity of the acetaldehyde dehydrogenase 2 mediated anthracycline type chemotherapy drugs to tumor cells, thus remaindering the application of the acetaldehyde dehydrogenase 2 as the drug target for treating tumor cells with the anthracycline type chemotherapy drugs. Deletion or mutation of the acetaldehyde dehydrogenase 2 exists in 40% of populations in Asia, so that the application of the acetaldehyde dehydrogenase 2 has a broader application prospect. For patients without the deletion or the mutation of the acetaldehyde dehydrogenase 2, killing effects on tumor cells can be significantly enhanced through combination of the anthracycline type chemotherapy drugs and an inhibitor of the acetaldehyde dehydrogenase 2.